We are live on ! Find out more
ONCE

Spark Therapeutics
ONCE

Delisted

ONCE was delisted on the 16th of December, 2019.

121 hedge funds and large institutions have $1.54B invested in Spark Therapeutics in 2016 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 53 increasing their positions, 26 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

186% more capital inflows, than outflows

Capital inflows: $175M | Capital outflows: $61.4M

104% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 26

41% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 17

5% more funds holding

Funds holding: 115 → 121 (+6)

4.31% more ownership

Funds ownership: 79.19% → 83.5% (+4.3%)

8% more call options, than puts

Call options by funds: $5.22M | Put options by funds: $4.84M

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
121
Holders Change
+6
Holders Change %
+5.22%
% of All Funds
3.22%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
24
Increased
53
Reduced
26
Closed
17
Calls
$5.22​M
Puts
$4.84​M
Net Calls
+$376​K
Net Calls Change
-⁠$12.4​M

ONCE Hedge Fund Activity: Q3 2016 in Review

121 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics (ONCE) for Q3 2016, worth a combined $1.54B — up 24% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ONCE positions and 17 closed out — a net gain of 7 holders — while 53 added to existing stakes and 26 trimmed.

The largest buyer was Victory Capital Management, opening a new position worth an estimated $27.2M. The largest seller was Millennium Management, exiting entirely with an estimated $15.9M sold.

  • 121 institutional investors held Spark Therapeutics (ONCE) as of Q3 2016, up from 115 in Q2 2016.
  • Funds reported $1.54B of Spark Therapeutics stock for Q3 2016, up 24% quarter-over-quarter.
  • 24 funds opened new Spark Therapeutics positions in Q3 2016 and 17 closed out, a net change of +7 holders.
  • The largest Spark Therapeutics buyer in Q3 2016 was Victory Capital Management, an estimated $27.2M added.
  • The largest Spark Therapeutics seller in Q3 2016 was Millennium Management, an estimated $15.9M sold.

Based on aggregated 13F filings for Q3 2016.